Scott Braunstein
CIK 1643875 · CHAIRMAN AND CEO · last filed 2026-09-11
Scott Braunstein is a CHAIRMAN AND CEO who has filed 57 SEC Form 4 insider transactions across 10 companies since 2015. The most recent filing, for ATAI, was dated Sep 11, 2026. Across all open-market trades the lifetime net is +$23.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $610.6K across reported positions. 8 SEC filings were submitted jointly with Pacira BioSciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$610.6K
10
57
$23.1K
Filer Profile
3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR, MI 48108
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATAI | Director | — | $7.35 | — | $0 | 5 | 2026-09-11 |
| CRBU | Director | — | $1.29 | — | $0 | 5 | 2026-02-20 |
| RAPT Therapeutics, Inc. (RAPT) Delisted | Director | 4,956 | $58.01 | $287.5K | $0 | 2 | 2026-02-02 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | CHAIRMAN AND CEO | 179,536 | $0.55 | $98.7K | -$61.5K | 15 | 2025-02-11 |
| TREVENA INC (TRVN) Delisted | Director | — | $0.01 | — | $0 | 7 | 2024-06-17 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Director | — | $33.99 | — | $0 | 3 | 2021-06-04 |
| TARA | Director | 26,500 | $3.54 | $93.8K | $0 | 3 | 2020-06-11 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 31,780 | $0.87 | $27.5K | $0 | 3 | 2020-01-03 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 5,019 | $3.18 | $16.0K | $0 | 5 | 2019-05-31 |
| PCRX | Chief Operating Officer | 20,982 | $24.63 | $516.8K | $84.6K | 7 | 2018-01-05 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-11 | ATAI | Disp (D) | — | $0 | EDGAR |
| 2026-06-08 | ATAI | Grant (A) | — | $0 | EDGAR |
| 2026-03-05 | — | Mixed | −4,956 | $0 | |
| 2026-02-20 | CRBU | Grant (A) | — | $0 | EDGAR |
| 2026-02-02 | RAPT Therapeutics, Inc. (RAPT) Delisted | Grant (A) | +4,956 | $0 | EDGAR |
| 2025-11-06 | ATAI | Grant (A) | — | $0 | EDGAR |
| 2025-06-27 | ATAI | Grant (A) | — | $0 | EDGAR |
| 2025-06-24 | RAPT Therapeutics, Inc. (RAPT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-21 | CRBU | Grant (A) | — | $0 | EDGAR |
| 2025-02-11 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Mixed | −298,667 | -$161.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.